Predictive Factors for Rheumatoid Arthritis Flare After Switching From Intravenous to Subcutaneous Formulation of Tocilizumab in Real-World Practice.
Soo Min AhnJi-Seon OhHyun Mi HeoSeokchan HongChang-Keun LeeBin YooYong-Gil KimPublished in: Journal of Korean medical science (2022)
MTX non-use and high dose of TCZ-IV per weight were associated with a risk of RA flare after switching to TCZ-SC. RA patients with these factors need to be carefully observed for flare after switching from TCZ-IV to TCZ-SC.